Salwa El Tawil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Salwa El Tawil has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Keith W. Muir
School of Psychology and Neuroscience, University of Glasgow, United Kingdom (K.W.M.).
3 shared publications - Alexander Zimprich
Department of Neurology, Medical University of Vienna, Vienna 1090, Austria
2 shared publications Eva Reinthaler
Department of Clinical Neurology, Medical University of Vienna, 1090 Vienna, Austria
2 shared publications- Grant Mair
Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, UK
2 shared publications - Joanna Marguerite Wardlaw
Centre for Clinical Brain Sciences, UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
2 shared publications - Sherif Edris
Biological Sciences Department, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia
2 shared publications
Latest Publications
- Open Access
- 1 June 2025
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- p. 1-32
Multimodal versus non-contrast computed tomography for assessment of acute ischaemic stroke: the PRACTISE RCT
Background: Non-contrast computed tomography has low sensitivity to brain ischaemia. Higher sensitivity of computed tomography perfusion and computed tomography angiography may identify more thrombolysis-eligible patients, but the role of these imaging modalities in thrombolysis treatment decisions within 4.5 hours is unclear. We hypothesised that multimodal computed tomography (non-contrast computed tomography + computed tomography angiography + computed tomography perfusion) would modify treatment decisions with net increase in thrombolysis rates. Design: Prospective, randomised controlled clinical trial. Setting: Hospital acute stroke services. Participants: Adults with clinically suspected acute ischaemic stroke eligible for intravenous thrombolytic therapy. Interventions: 1 : 1 randomisation to non-contrast computed tomography or multimodal imaging (non-contrast computed tomography + computed tomography angiography + computed tomography perfusion). Main outcome measures: Proportion treated with intravenous thrombolytic therapy (primary outcome). Secondary end points: functional recovery at 3 months, early neurological recovery, times to decision making and treatment delivery, safety (mortality, incidence of symptomatic intracerebral haemorrhage). Results: Over 36 months, 11 United Kingdom sites randomised 271 patients (134 multimodal computed tomography, 137 non-contrast computed tomography). The mean age was 67.6 years and the median National Institutes of Health Stroke Scale score was 6 (interquartile range 3–12). After initial non-contrast computed tomography, 114/134 multimodal computed tomography and 108/137 non-contrast computed tomography patients were found to be thrombolysis-eligible. Significantly fewer multimodal computed tomography patients received thrombolytic therapy (56/114, 49.1%) compared to non-contrast computed tomography alone [73/108, 67.6%, odds ratio 0.46 (95% confidence interval: 0.25 to 0.83), p = 0.0102]. Treatment decision and delivery times, early neurological recovery and day 90 functional outcomes did not differ significantly between groups. Mortality was 6/114 (5.3%) in the multimodal computed tomography group and 11/108 (10.2%) in non-contrast computed tomography alone [odds ratio 0.46 (95% confidence interval: 0.16 to 1.31), p = 0.147]. Symptomatic intracerebral haemorrhage occurred in two patients, both in the non-contrast computed tomography group. There were no significant interactions between stroke subgroups by severity or syndrome. The proportion of patients with confirmed stroke on follow-up imaging at 24 hours did not differ significantly between groups. Limitations: Recruitment was lower than the planned sample size, but thrombolysis rate was much higher than originally estimated (60% overall vs. 25% estimated). Computed tomography interpretation and treatment decisions were at the discretion of clinicians. Findings reflect United Kingdom practice in a predominantly less severe stroke clinical population. Conclusions: Multimodal computed tomography resulted in significantly fewer patients receiving thrombolysis, principally because multimodal imaging did not identify relevant therapeutic targets (perfusion defects or intracranial vessel occlusion). Treatment decision times and clinical outcomes did not differ significantly between groups. Fewer deaths and no symptomatic intracerebral haemorrhages occurred in the multimodal computed tomography group. Future work: Further investigation of potentially lower mortality and symptomatic intracerebral haemorrhage with multimodal imaging is of potential clinical importance. Trial registration: This trial is registered as ClinicalTrials.gov identifier NCT02360670. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 11/100/78) and is published in full in Efficacy and Mechanism Evaluation; Vol. 12, No. 6. See the NIHR Funding and Awards website for further award information.
- 1 June 2025
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- p. 1-32
Open AccessMultimodal versus non-contrast computed tomography for assessment of acute ischaemic stroke: the PRACTISE RCT
Background: Non-contrast computed tomography has low sensitivity to brain ischaemia. Higher sensitivity of computed tomography perfusion and computed tomography angiography may identify more thrombolysis-eligible patients, but the role of these imaging modalities in thrombolysis treatment decisions within 4.5 hours is unclear. We hypothesised that multimodal computed tomography (non-contrast computed tomography + computed tomography angiography + computed tomography perfusion) would modify treatment decisions with net increase in thrombolysis rates. Design: Prospective, randomised controlled clinical trial. Setting: Hospital acute stroke services. Participants: Adults with clinically suspected acute ischaemic stroke eligible for intravenous thrombolytic therapy. Interventions: 1 : 1 randomisation to non-contrast computed tomography or multimodal imaging (non-contrast computed tomography + computed tomography angiography + computed tomography perfusion). Main outcome measures: Proportion treated with intravenous thrombolytic therapy (primary outcome). Secondary end points: functional recovery at 3 months, early neurological recovery, times to decision making and treatment delivery, safety (mortality, incidence of symptomatic intracerebral haemorrhage). Results: Over 36 months, 11 United Kingdom sites randomised 271 patients (134 multimodal computed tomography, 137 non-contrast computed tomography). The mean age was 67.6 years and the median National Institutes of Health Stroke Scale score was 6 (interquartile range 3–12). After initial non-contrast computed tomography, 114/134 multimodal computed tomography and 108/137 non-contrast computed tomography patients were found to be thrombolysis-eligible. Significantly fewer multimodal computed tomography patients received thrombolytic therapy (56/114, 49.1%) compared to non-contrast computed tomography alone [73/108, 67.6%, odds ratio 0.46 (95% confidence interval: 0.25 to 0.83), p = 0.0102]. Treatment decision and delivery times, early neurological recovery and day 90 functional outcomes did not differ significantly between groups. Mortality was 6/114 (5.3%) in the multimodal computed tomography group and 11/108 (10.2%) in non-contrast computed tomography alone [odds ratio 0.46 (95% confidence interval: 0.16 to 1.31), p = 0.147]. Symptomatic intracerebral haemorrhage occurred in two patients, both in the non-contrast computed tomography group. There were no significant interactions between stroke subgroups by severity or syndrome. The proportion of patients with confirmed stroke on follow-up imaging at 24 hours did not differ significantly between groups. Limitations: Recruitment was lower than the planned sample size, but thrombolysis rate was much higher than originally estimated (60% overall vs. 25% estimated). Computed tomography interpretation and treatment decisions were at the discretion of clinicians. Findings reflect United Kingdom practice in a predominantly less severe stroke clinical population. Conclusions: Multimodal computed tomography resulted in significantly fewer patients receiving thrombolysis, principally because multimodal imaging did not identify relevant therapeutic targets (perfusion defects or intracranial vessel occlusion). Treatment decision times and clinical outcomes did not differ significantly between groups. Fewer deaths and no symptomatic intracerebral haemorrhages occurred in the multimodal computed tomography group. Future work: Further investigation of potentially lower mortality and symptomatic intracerebral haemorrhage with multimodal imaging is of potential clinical importance. Trial registration: This trial is registered as ClinicalTrials.gov identifier NCT02360670. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 11/100/78) and is published in full in Efficacy and Mechanism Evaluation; Vol. 12, No. 6. See the NIHR Funding and Awards website for further award information.
- 15 October 2019
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 28 (12) , 104445
Stroke Patients' Status Post-Acute Phase of Illness. How Is It and How Ought It to Be: Ain Shams University Experience
- 15 October 2019
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 28 (12) , 104445
Stroke Patients' Status Post-Acute Phase of Illness. How Is It and How Ought It to Be: Ain Shams University Experience
- Open Access
- 1 April 2017
- Published by Elsevier in Clinical Medicine
- Vol. 17 (2) , 161-165
Thrombolysis and thrombectomy for acute ischaemic stroke
The likelihood of disability-free recovery after acute ischemic stroke is significantly improved by reperfusion either by intravenous thrombolytic drug treatment or with endovascular mechanical thrombectomy in selected cases. The use of intravenous thrombolysis is limited by the short treatment window and you need to assess individual balance of benefit and risk of symptomatic intracranial haemorrhage. Benefit is greater for shorter onset-to-reperfusion time intervals, requiring optimisation of pre-hospital and in-hospital pathways. Symptomatic haemorrhage is more likely with more severe strokes, but a greater proportion of patients are left free of disability than suffer a treatment-related haemorrhage at all levels of severity. Extracranial haemorrhage and orolingual angioedema are less common complications. Endovascular mechanical thrombectomy can be used in selected patients with imaging-proven large artery occlusion. Successful therapy depends on well-organised services that can deliver treatment within a short time window at centres with adequate expertise to perform the procedure.
- 1 April 2017
- Published by Elsevier in Clinical Medicine
- Vol. 17 (2) , 161-165
Open AccessThrombolysis and thrombectomy for acute ischaemic stroke
The likelihood of disability-free recovery after acute ischemic stroke is significantly improved by reperfusion either by intravenous thrombolytic drug treatment or with endovascular mechanical thrombectomy in selected cases. The use of intravenous thrombolysis is limited by the short treatment window and you need to assess individual balance of benefit and risk of symptomatic intracranial haemorrhage. Benefit is greater for shorter onset-to-reperfusion time intervals, requiring optimisation of pre-hospital and in-hospital pathways. Symptomatic haemorrhage is more likely with more severe strokes, but a greater proportion of patients are left free of disability than suffer a treatment-related haemorrhage at all levels of severity. Extracranial haemorrhage and orolingual angioedema are less common complications. Endovascular mechanical thrombectomy can be used in selected patients with imaging-proven large artery occlusion. Successful therapy depends on well-organised services that can deliver treatment within a short time window at centres with adequate expertise to perform the procedure.
- 14 March 2017
- Published by SAGE Publications in International Journal of Stroke
- Vol. 12 (6) , 671-678
Penumbra and re-canalization acute computed tomography in ischemic stroke evaluation: PRACTISE study protocol
Rationale: Multimodal imaging, including computed tomography angiography and computed tomography perfusion imaging, yields additional information on intracranial vessels and brain perfusion and can differentiate between ischemic core and penumbra which may affect patient selection for intravenous thrombolysis. Hypothesis: The use of multimodal imaging will increase the number of patients receiving intravenous thrombolysis and lead to better treatment outcomes. Sample size: 400 patients. Methods and design: PRACTISE is a prospective, multicenter, randomized, controlled trial in which patients presenting within 4.5 h of symptom onset are randomized to either the current evidence-based imaging (NCCT alone) or additional multimodal computed tomography imaging (NCCT + computed tomography angiography + computed tomography perfusion). Clinical decisions on intravenous recombinant tissue plasminogen activator are documented. Total imaging time in both arms and time to initiation of treatment delivery in those treated with intravenous recombinant tissue plasminogen activator, is recorded. Follow-up will include brain imaging at 24 h to document infarct size, the presence of edema and the presence of intra-cerebral hemorrhage. Clinical evaluations include NIHSS score at baseline, 24 h and day 7 ± 2, and mRS at day 90 to define functional outcomes. Study outcomes: The primary outcome is the proportion of patients receiving intravenous recombinant tissue plasminogen activator. Secondary end-points evaluate times to decision-making, comparison of different image processing software and clinical outcomes at three months. Discussion: Multimodal computed tomography is a widely available tool for patient selection for revascularization therapy, but it is currently unknown whether the use of additional imaging in all stroke patients is beneficial. The study opened for recruitment in March 2015 and will provide data on the value of multimodal imaging in treatment decisions for acute stroke.
- 14 March 2017
- Published by SAGE Publications in International Journal of Stroke
- Vol. 12 (6) , 671-678
Penumbra and re-canalization acute computed tomography in ischemic stroke evaluation: PRACTISE study protocol
Rationale: Multimodal imaging, including computed tomography angiography and computed tomography perfusion imaging, yields additional information on intracranial vessels and brain perfusion and can differentiate between ischemic core and penumbra which may affect patient selection for intravenous thrombolysis. Hypothesis: The use of multimodal imaging will increase the number of patients receiving intravenous thrombolysis and lead to better treatment outcomes. Sample size: 400 patients. Methods and design: PRACTISE is a prospective, multicenter, randomized, controlled trial in which patients presenting within 4.5 h of symptom onset are randomized to either the current evidence-based imaging (NCCT alone) or additional multimodal computed tomography imaging (NCCT + computed tomography angiography + computed tomography perfusion). Clinical decisions on intravenous recombinant tissue plasminogen activator are documented. Total imaging time in both arms and time to initiation of treatment delivery in those treated with intravenous recombinant tissue plasminogen activator, is recorded. Follow-up will include brain imaging at 24 h to document infarct size, the presence of edema and the presence of intra-cerebral hemorrhage. Clinical evaluations include NIHSS score at baseline, 24 h and day 7 ± 2, and mRS at day 90 to define functional outcomes. Study outcomes: The primary outcome is the proportion of patients receiving intravenous recombinant tissue plasminogen activator. Secondary end-points evaluate times to decision-making, comparison of different image processing software and clinical outcomes at three months. Discussion: Multimodal computed tomography is a widely available tool for patient selection for revascularization therapy, but it is currently unknown whether the use of additional imaging in all stroke patients is beneficial. The study opened for recruitment in March 2015 and will provide data on the value of multimodal imaging in treatment decisions for acute stroke.
- Open Access
- 1 December 2016
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 1 (4) , 264-271
How many stroke patients might be eligible for mechanical thrombectomy?
Introduction: Recent studies showed improved patient outcomes with endovascular treatment of acute stroke compared to medical care, including IV rtPA, alone. Seven trials have reported results, each using different clinical and imaging criteria for patient selection. We compared eligibility for different trial protocols to estimate the number of patients eligible for treatment. Patients and methods: Patient data were extracted from a single centre database that combined patients recruited to three clinical studies, each of which obtained both CTA and CTP within 6 h of stroke onset. The published inclusion and exclusion criteria of seven intervention trials (MR CLEAN, EXTEND–IA, ESCAPE, SWIFT-PRIME, REVASCAT, THERAPY and THRACE) were applied to determine the proportion that would be eligible for each of these studies. Results: A total of 263 patients was included. Eligibility for IAT in individual trials ranged from 53% to 3% of patients; 17% were eligible for four trials and under 10% for two trials. Only three patients (1%) were eligible for all studies. The most common cause of exclusion was absence of large artery occlusion (LAO) on CTA. When applying simplified criteria requiring an ASPECT score > 6, 16% were eligible for IAT, but potentially 40% of these patients were excluded by perfusion criteria and more than half by common NIHSS thresholds. Conclusion: Around 15% of patients presenting within 6 h of stroke onset were potentially eligible for IAT, but clinical trial eligibility criteria have much more limited overlap than is commonly assumed and only 1% of patients fulfilled criteria for all recent trials.
- 1 December 2016
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 1 (4) , 264-271
Open AccessHow many stroke patients might be eligible for mechanical thrombectomy?
Introduction: Recent studies showed improved patient outcomes with endovascular treatment of acute stroke compared to medical care, including IV rtPA, alone. Seven trials have reported results, each using different clinical and imaging criteria for patient selection. We compared eligibility for different trial protocols to estimate the number of patients eligible for treatment. Patients and methods: Patient data were extracted from a single centre database that combined patients recruited to three clinical studies, each of which obtained both CTA and CTP within 6 h of stroke onset. The published inclusion and exclusion criteria of seven intervention trials (MR CLEAN, EXTEND–IA, ESCAPE, SWIFT-PRIME, REVASCAT, THERAPY and THRACE) were applied to determine the proportion that would be eligible for each of these studies. Results: A total of 263 patients was included. Eligibility for IAT in individual trials ranged from 53% to 3% of patients; 17% were eligible for four trials and under 10% for two trials. Only three patients (1%) were eligible for all studies. The most common cause of exclusion was absence of large artery occlusion (LAO) on CTA. When applying simplified criteria requiring an ASPECT score > 6, 16% were eligible for IAT, but potentially 40% of these patients were excluded by perfusion criteria and more than half by common NIHSS thresholds. Conclusion: Around 15% of patients presenting within 6 h of stroke onset were potentially eligible for IAT, but clinical trial eligibility criteria have much more limited overlap than is commonly assumed and only 1% of patients fulfilled criteria for all recent trials.
- 1 November 2016
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 42, 60-62
Adult onset Rasmussen’s encephalitis associated with reflex language induced seizures responsive to Rituximab therapy
- 1 November 2016
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 42, 60-62
Adult onset Rasmussen’s encephalitis associated with reflex language induced seizures responsive to Rituximab therapy
- Open Access
- 21 January 2015
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 86 (11) , 1279-1280
Variant Creutzfeldt-Jakob disease in older patients
Variant Creutzfeldt-Jakob disease (vCJD) is a zoonotic disease caused by cross-species transmission of bovine spongiform encephalopathy with a median age at onset of 27 years. In 1996, when the first cases were described, a clinicopathological phenotype distinct from sporadic CJD was defined and diagnostic criteria with a high sensitivity and specificity for vCJD have been validated.1 All definite and probable cases of vCJD (201/218) have been methionine homozygous (MM) at codon 129 of the prion protein gene ( PRNP ). If cases with the other PRNP -129 genotypes (MV, VV) have longer incubation periods, and are exposed at the same age, they will be older by the time they develop symptomatic disease. In addition, patients over 50 are more likely undergo surgical procedures and receive blood transfusions than younger patients and are, therefore, at greater risk of secondary vCJD. Future vCJD cases are likely to occur in older groups than in the primary epidemic. An important question is whether these patients have the same clinical phenotype and pattern of investigation findings as previously described. A review of the 177 probable and definite vCJD cases referred to the UK surveillance system between 1995 and 2014 identified six cases aged over 55 years at the onset of symptoms. All the cases developed progressive cognitive impairment and additional neurological features which are unusual in the more common forms …
- 21 January 2015
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 86 (11) , 1279-1280
Open AccessVariant Creutzfeldt-Jakob disease in older patients
Variant Creutzfeldt-Jakob disease (vCJD) is a zoonotic disease caused by cross-species transmission of bovine spongiform encephalopathy with a median age at onset of 27 years. In 1996, when the first cases were described, a clinicopathological phenotype distinct from sporadic CJD was defined and diagnostic criteria with a high sensitivity and specificity for vCJD have been validated.1 All definite and probable cases of vCJD (201/218) have been methionine homozygous (MM) at codon 129 of the prion protein gene ( PRNP ). If cases with the other PRNP -129 genotypes (MV, VV) have longer incubation periods, and are exposed at the same age, they will be older by the time they develop symptomatic disease. In addition, patients over 50 are more likely undergo surgical procedures and receive blood transfusions than younger patients and are, therefore, at greater risk of secondary vCJD. Future vCJD cases are likely to occur in older groups than in the primary epidemic. An important question is whether these patients have the same clinical phenotype and pattern of investigation findings as previously described. A review of the 177 probable and definite vCJD cases referred to the UK surveillance system between 1995 and 2014 identified six cases aged over 55 years at the onset of symptoms. All the cases developed progressive cognitive impairment and additional neurological features which are unusual in the more common forms …
- Open Access
- 21 March 2013
- Published by Oxford University Press (OUP) in Brain
- Vol. 136 (4) , 1155-1160
Autosomal recessive cortical myoclonic tremor and epilepsy: association with a mutation in the potassium channel associated gene CNTN2
We characterize a consanguineous Egyptian family with an autosomal recessively inherited familial cortical myoclonic tremor and epilepsy. We used multipoint linkage analysis to map the causative mutation to a 12.7 megabase interval within 1q31.3–q32.2 with a log of odds score of 3.6. For further investigation of the linked region in an efficient and unbiased manner, we performed exome sequencing. Within the suspected region we identified a homozygous single base pair deletion (c.503_503delG) leading to a frameshift in the coding region of the sixth exon of CNTN2 alias TAG-1 (p.Trp168fs), which segregated in the respective family. Many studies point towards an important role of the CNTN2 product contactin 2 in neuronal excitability. Contactin 2, a glycosylphosphatidylinositol-anchored neuronal membrane protein, and another transmembrane protein called contactin associated protein-like 2 (CNTNAP2 alias CASPR2) are together necessary to maintain voltage-gated potassium channels at the juxtaparanodal region. CNTN2 knockout mice were previously reported to suffer from spontaneous seizures and mutations in the CNTNAP2 gene have been described to cause epilepsy in humans. To further delineate the role of CNTN2 in patients with epilepsy, we sequenced the coding exons in 189 Caucasian patients with epilepsy. No recessive mutation was detected and heterozygote carriers of rare CNTN2 variants do not seem to be predisposed to epilepsy. Given the severity of the mutation and the proposed function of the gene, we consider this mutation as the most likely cause for cortical myoclonic tremor and epilepsy in this family.
- 21 March 2013
- Published by Oxford University Press (OUP) in Brain
- Vol. 136 (4) , 1155-1160
Open AccessAutosomal recessive cortical myoclonic tremor and epilepsy: association with a mutation in the potassium channel associated gene CNTN2
We characterize a consanguineous Egyptian family with an autosomal recessively inherited familial cortical myoclonic tremor and epilepsy. We used multipoint linkage analysis to map the causative mutation to a 12.7 megabase interval within 1q31.3–q32.2 with a log of odds score of 3.6. For further investigation of the linked region in an efficient and unbiased manner, we performed exome sequencing. Within the suspected region we identified a homozygous single base pair deletion (c.503_503delG) leading to a frameshift in the coding region of the sixth exon of CNTN2 alias TAG-1 (p.Trp168fs), which segregated in the respective family. Many studies point towards an important role of the CNTN2 product contactin 2 in neuronal excitability. Contactin 2, a glycosylphosphatidylinositol-anchored neuronal membrane protein, and another transmembrane protein called contactin associated protein-like 2 (CNTNAP2 alias CASPR2) are together necessary to maintain voltage-gated potassium channels at the juxtaparanodal region. CNTN2 knockout mice were previously reported to suffer from spontaneous seizures and mutations in the CNTNAP2 gene have been described to cause epilepsy in humans. To further delineate the role of CNTN2 in patients with epilepsy, we sequenced the coding exons in 189 Caucasian patients with epilepsy. No recessive mutation was detected and heterozygote carriers of rare CNTN2 variants do not seem to be predisposed to epilepsy. Given the severity of the mutation and the proposed function of the gene, we consider this mutation as the most likely cause for cortical myoclonic tremor and epilepsy in this family.
- 1 December 2011
- Published by Elsevier in Journal of Infection
- Vol. 63 (6) , e116
Status epilepticus as an atypical presentation of brain disease
- 1 December 2011
- Published by Elsevier in Journal of Infection
- Vol. 63 (6) , e116
Status epilepticus as an atypical presentation of brain disease
- 1 August 2009
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 15 (7) , 532-534
PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson's disease
- 1 August 2009
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 15 (7) , 532-534
PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson's disease